Table 3 5-year estimate of cumulative incidence and hazard ratio by outcome, risk category and gene signature.

From: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

 

Risk category

N

TTR

TTDR

BCSS

   

5-year cumulative incidencea (95%CI)

Univariate analysisb HR (95%CI)

Multivariate analysisc HR (95%CI)

5-year cumulative incidencea (95%CI)

Univariate analysisb HR (95%CI)

Multivariate analysisc HR (95%CI)

5-year cumulative incidencea (95%CI)

Univariate analysisb HR (95%CI)

Oncotype Dx-trained

   

P-value ≤ 0.001

P-value = 0.039

 

P-value = 0.002

P-value = 0.051

 

P-value = 0.004

High

106

23.4% (15.1–32.7)

3.47 (1.84–6.54)

2.32 (0.99–5.45)

22.0% (13.8–31.5)

3.47 (1.74–6.92)

2.29 (0.90–5.80)

13.7% (7.1–22.4)

4.90 (1.83–13.15)

Intermediate

146

16.2% (9.8–23.9)

2.32 (1.23–4.38)

2.63 (1.25–5.56)

13.2% (7.4–20.7)

2.17 (1.08–4.34)

2.89 (1.23–6.78)

5.0% (1.8–10.6)

3.10 (1.14–8.39)

Low

129

8.4% (3.9–15.2)

Reference

Reference

6.6% (2.6–13.0)

Reference

Reference

2.0% (0.4–7.1)

Reference

ROR-PT-trainedd

   

P-value = 0.002

P-value = 0.422

 

P-value = 0.004

P-value = 0.467

 

P-value = 0.004

High

174

24.0% (17.1–31.5)

2.89 (1.17–7.16)

2.34 (0.63–8.60)

22.1% (15.4–29.7)

3.15 (1.07–9.26)

2.85 (0.50–16.39)

11.1% (6.2–17.4)

6.01 (0.80–45.36)

Intermediate

152

7.6% (3.5–13.9)

1.29 (0.50–3.34)

1.84 (0.53–6.38)

6.0% (2.4–12.0)

1.37 (0.45–4.24)

2.24 (0.41–12.35)

0.7% (0.1–3.7)

2.12 (0.27–16.89)

Low

36

3.7% (0.3–16.3)

Reference

Reference

3.7% (0.3–16.3)

Reference

Reference

4.6% (0.3–19.8) (1 event)

Reference

IHC4 RNA-like

   

P-value = 0.007

P-value = 0.085

 

P-value = 0.016

P-value = 0.099

 

P-value = 0.056

High

60

24.6% (13.8–37.1)

3.53 (1.55–8.01)

2.53 (0.91–7.06)

21.4% (11.2–33.9)

3.48 (1.36–8.90)

2.44 (0.73–8.12)

11.9% (4.7–22.8)

4.09 (1.24–13.42)

Intermediate

212

16.1% (10.9–22.2)

2.58 (1.28–5.22)

2.49 (1.11–5.59)

14.4% (9.4–20.4)

2.85 (1.29–6.27)

2.78 (1.09–7.12)

6.6% (3.4–11.4)

2.82 (0.99–8.03)

Low

109

8.9% (3.8–16.7)

Reference

Reference

6.6% (2.4–13.8)

Reference

Reference

3.0% (0.5–9.5)

Reference

MammaPrint-trained

   

P-value = 0.002

P-value = 0.824

 

P-value = 0.001

P-value = 0.594

 

P-value ≤ 0.001

High

177

21.9% (15.3–29.4)

2.02 (1.29–3.17)

1.09 (0.51–2.36)

20.7% (14.1–28.3)

2.30 (1.40–3.78)

1.25 (0.55–2.83)

12.1% (6.9–18.7)

3.04 (1.59–5.82)

Low

204

10.0% (5.9–15.4)

Reference

Reference

7.2% (3.8–12.2)

Reference

Reference

2.1% (0.6–5.6)

Reference

95-gene signature

   

P-value ≤ 0.001

P-value = 0.149

 

P-value = 0.001

P-value = 0.378

 

P-value ≤ 0.001

High

201

20.0% (14.2–26.5)

2.42 (1.49–3.93)

1.55 (0.86–2.80)

17.8% (12.2–24.2)

2.44 (1.43–4.15)

1.35 (0.69–2.63)

10.9% (6.4–16.7)

3.94 (1.85–8.37)

Low

180

10.2% (5.6–16.2)

Reference

Reference

8.2% (4.1–14.0)

Reference

Reference

1.7% (0.3–5.5)

Reference

GGI-like

   

P-value =0.001

P-value = 0.063

 

P-value = 0.001

P-value = 0.059

 

P-value ≤ 0.001

High

242

20.5% (15.0–26.6)

2.48 (1.43–4.31)

2.03 (0.96–4.27)

18.7% (13.3–24.8)

2.90 (1.55–5.45)

2.32 (0.97–5.55)

9.8% (5.8–14.9)

5.41 (1.95–15.06)

Low

139

6.7% (2.9–12.6)

Reference

Reference

4.1% (1.3–9.4)

Reference

Reference

0.9% (0.1–4.5)

Reference

  1. 95%CI 95% confidence interval, HR hazard ratio, N number of patients, TTR time to relapse, TTDR time to distant relapse, BCSS breast cancer-specific survival, GGI Genomic Grade Index.
  2. aCumulative incidence rates and corresponding 95%CI estimated by cumulative incidence function accounting for deaths not preceded by a distant relapse as competing risks.
  3. bP-value based on Fine and Gray test.
  4. cFine and Gray model adjusted for age, grade, nodal status and tumor size and treatment variables (adjuvant chemotherapy, radiotherapy, endocrine treatment). P-value based on Wald test.
  5. dROR-PT-trained uses the trained ROR-PT score, including tumor size; 19 missing values due to missing tumor size.
Back to article page